EyePoint Pharmaceuticals Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyePoint Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EyePoint Pharmaceuticals stock.
View analyst ratings for EyePoint Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given EyePoint Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but EyePoint Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

EyePoint Pharmaceuticals saw a increase in short interest in the month of May. As of May 14th, there was short interest totaling 1,230,000 shares, an increase of 116.3% from the April 29th total of 568,700 shares. Based on an average trading volume of 235,900 shares, the days-to-cover ratio is presently 5.2 days. Currently, 5.9% of the company's shares are sold short.
View EyePoint Pharmaceuticals' Short Interest.

EyePoint Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) announced its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.02. The firm had revenue of $7.32 million for the quarter, compared to analyst estimates of $8.29 million. EyePoint Pharmaceuticals had a negative trailing twelve-month return on equity of 119.41% and a negative net margin of 129.85%.
View EyePoint Pharmaceuticals' earnings history.

EyePoint Pharmaceuticals' stock was trading at $10.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EYPT shares have decreased by 8.6% and is now trading at $9.60.
View which stocks have been most impacted by COVID-19.

EyePoint Pharmaceuticals's stock reverse split before market open on Wednesday, December 9th 2020. The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 8th 2020. An investor that had 100 shares of EyePoint Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

4 analysts have issued 1-year target prices for EyePoint Pharmaceuticals' stock. Their forecasts range from $8.50 to $25.00. On average, they expect EyePoint Pharmaceuticals' stock price to reach $17.63 in the next twelve months. This suggests a possible upside of 83.6% from the stock's current price.
View analysts' price targets for EyePoint Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to EyePoint Pharmaceuticals include Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Talis Biomedical (TLIS), Precipio (PRPO), Astrotech (ASTC), HTG Molecular Diagnostics (HTGM), Scientific Industries (SCND), BioForce Nanosciences (BFNH), Pressure BioSciences (PBIO), Arrayit (ARYC), DiaSys (DYXC), Orthometrix (OMRX) and PositiveID (PSID).
View all of EYPT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other EyePoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Inovio Pharmaceuticals (INO), Verastem (VSTM), XOMA (XOMA), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX), Progenics Pharmaceuticals (PGNX), Corbus Pharmaceuticals (CRBP) and Dynavax Technologies (DVAX).

EyePoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

EyePoint Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Franklin Resources Inc. (10.05%), RA Capital Management L.P. (4.35%), Suvretta Capital Management LLC (4.11%), Janus Henderson Group PLC (2.34%), Samsara BioCapital LLC (1.57%) and Acuta Capital Partners LLC (1.33%). Company insiders that own EyePoint Pharmaceuticals stock include George Elston and Nancy Lurker.
View institutional ownership trends for EyePoint Pharmaceuticals.

EYPT stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC.
View insider buying and selling activity for EyePoint Pharmaceuticals or view top insider-selling stocks.

EYPT stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., RA Capital Management L.P., Suvretta Capital Management LLC, Janus Henderson Group PLC, Samsara BioCapital LLC, Acuta Capital Partners LLC, Silverarc Capital Management LLC, and Altium Capital Management LP. Company insiders that have bought EyePoint Pharmaceuticals stock in the last two years include George Elston, and Nancy Lurker.
View insider buying and selling activity for EyePoint Pharmaceuticals or or view top insider-buying stocks.

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EYPT stock can currently be purchased for approximately $9.60.

EyePoint Pharmaceuticals has a market capitalization of $275.91 million and generates $34.44 million in revenue each year. The company earns $-45,390,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis.

EyePoint Pharmaceuticals employs 98 workers across the globe.

The official website for EyePoint Pharmaceuticals is eyepointpharma.com.

EyePoint Pharmaceuticals is headquartered at 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472.

EyePoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]